Business
Gap To Layoff Hundreds Of Corporate Employees During Latest Round Of Cutbacks
Getty Images

The Gap’s stock is soaring, back to where it was in 1998... and 2012, and 2017, and 2020, and 2024

After years of store closures and slumping sales, the ’90s mall staple may finally be finding its footing.

The Y2K mall brand might be cool again — at least on Wall Street.

Yesterday, Gap reported operating profits for its fiscal year 2024 of $1.1 billion, up more than 80% on last year’s efforts, sending its shares up 13% in trading this morning.

It’s a sharp turnaround for the iconic but often struggling American retailer, which shrunk its footprint by closing over 340 stores and cutting 2,300 corporate jobs since 2020. At the heart of Gap’s struggles was Old Navy, which is actually the company’s largest brand, accounting for 56% of its sales. The label has lagged in recent years — first by being slow to pivot away from the pandemic-era comfort wear, then stumbling on an ambitious inclusive sizing rollout that left stores overloaded with XXLs and XSs while running out of core medium sizes, per the WSJ.

Sales were consistently slipping until August 2023, when ex-Mattel exec Richard Dickson, the man behind Barbie’s revival, took the top job. Then came Zac Posen, the Project Runway-famous designer, as Gap’s creative director, bringing the ’90s fashion staple back into the spotlight — from celebrities gracing Met Gala red carpet in a Gap gown to Timothée Chalamet rocking Gap at an Oscars dinner.

GAP renaissance
Sherwood News

The results are starting to show: Old Navy just delivered one of its highest annual net sales ever, while the Gap brand posted a 7% jump in comparable sales, now “back in the cultural conversation,” Dickson said in yesterday’s earnings call.

Gap also isn’t sweating tariffs. According to the CFO, the company sources less than 10% from China and under 1% from Mexico and Canada combined.

Of course, even with Gap soaring this morning, the company’s stock remains stuck in the $10 to $30 range that it’s been in for much of the last three decades.

Go Deeper: Boom, bust, back from the dead: Why are mall retailers the most interesting stocks on the market?

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.